{"page":{"totalFilteredElements":11},"studies":[{"active":true,"description":"<div>A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2</div><div>Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma</div><div><br /></div>","eudractNumber":"2024-517140-65","id":11953,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"BCL (B-cell lymphoma)","id":"mt_202"},{"name":"BCL-2","id":"mt_74"},{"name":"Translokation","id":"mt_244"},{"name":"t(11;14)","id":"mt_78"}],"nctNumber":"NCT06953960","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2026-04-30T12:43:33+02:00","shortTitle":"Multiple Myeloma: Evaluate the Safety and Efficacy of ABBV-453 in Monotherapy or in Combination with Antimyeloma Regimens","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]}]}